Corvus Pharmaceuticals, Inc

78 articles about Corvus Pharmaceuticals, Inc

• Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease

  9/22/2021

  Corvus Pharmaceuticals, Inc. provided an update on its development programs in oncology and infectious disease for mupadolimab, a humanized monoclonal antibody directed against CD73 with a proposed dual mechanism of activating B cells to generate immune responses to viruses and tumor antigens, and inhibiting the production of immunosuppressive adenosine in the tumor micro environment.

• Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences in September 2021

  9/7/2021

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the Company’s management will participate in two upcoming investor conferences in September/

• Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in ChinaCorvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021

  8/16/2021

  Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that an IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), for the initiation of a Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T cell lymphomas has been accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA).

• Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

  8/2/2021

  Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2021.

• Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

  7/15/2021

  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has discontinued its Phase 3 study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering serious infection and hospitalizations

• Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

  5/25/2021

  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference.

• Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

  5/5/2021

  Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximately $10 million of its common shares pursuant to the Company’s ATM program established on March 9, 2020 through Jefferies LLC (“Jefferies”), acting as sales agent.

• Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

  4/29/2021

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, provided a business update and reported financial results for the first quarter ended March 31, 2021.

• Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

  3/25/2021

  Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2020.

• Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

  3/5/2021

  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will participate in two upcoming investor conferences

• Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

  2/17/2021

  Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares of common stock pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, at a price to the public of $3.50 per share. All shares in the offeri

• Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

  2/12/2021

  Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of $3.50 per share, for gross proceeds of $30.0 million before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Corvus

• Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock - Feb 11, 2021

  2/11/2021

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has commenced an underwritten public offering of shares of its common stock.

• Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

  2/4/2021

  Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure Randomized, double-blind, placebo-controlled study expected to enroll ~1,000 patients across global sites with results expected in Q4 2021 Company to host conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT

• Corvus Announces Participation in Upcoming Investor Conferences

  9/8/2020

  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following investor conferences:

• Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  8/4/2020

  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference.

• Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

  7/30/2020

  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the second quarter ended June 30, 2020.

• Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

  7/23/2020

  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2020 financial results.  The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and using the conference ID 10010533. T

• 

  Biopharma Update on the Novel Coronavirus: July 8

  7/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.

• Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19

  7/7/2020

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.